Within the integrated industrial ecosystem of Brother Enterprises Holding Co., Ltd., Zhejiang Brothers Pharmaceutical Co., Ltd. serves as the group's dedicated platform for the research, registration, commercialization, and marketing of pharmaceutical formulations. Unlike the Jiangsu and Jiangxi production bases, which specialize in vitamins and active pharmaceutical ingredients (APIs), Zhejiang Brothers Pharmaceutical focuses on finished dosage forms, leveraging the group's internally manufactured APIs to build a diversified portfolio covering diagnostic imaging, cardiovascular disease, neurology, metabolic disorders, and nutritional supplementation.
By integrating API manufacturing with formulation development, the company completes Brother's "API-to-formulation" value chain and strengthens its position in the pharmaceutical industry.
Leveraging the group's in-house production of Iohexol and Iopamidol APIs at Jiangxi Brother Pharmaceutical, Zhejiang Brothers Pharmaceutical has successfully developed multiple contrast media injection products widely used in hospitals for CT enhancement and radiographic examinations.
Available in multiple iodine concentrations and packaging sizes, including 50 mL and 100 mL presentations, Iohexol Injection is a non-ionic, low-osmolar contrast medium indicated for contrast-enhanced CT imaging, angiography, and urography. The product offers excellent clinical safety and has been included in China's centralized volume-based procurement program.
Iopamidol Injection is a Class A product under China's national medical insurance system and is widely used in cerebral angiography, cardiovascular imaging, spinal examinations, and arthrography. Featuring low viscosity and excellent patient tolerance, the product received commercial approval in 2025, expanding the group's portfolio of premium diagnostic imaging products.
Because both APIs are manufactured internally within the Brother Group, Zhejiang Brothers Pharmaceutical benefits from greater cost control, stable supply, and enhanced competitiveness in both domestic and international markets.
The company has developed several oral formulations targeting chronic cardiovascular diseases such as hypertension and coronary artery disease. Multiple products are covered by China's medical insurance system and centralized procurement program, serving hospitals, healthcare institutions, and retail pharmacy chains.
Bisoprolol Fumarate is a selective beta-blocker indicated for hypertension, angina pectoris, and chronic heart failure. The company's 5 mg formulation has passed China's generic consistency evaluation and is widely prescribed in clinical practice.
Tranexamic Acid Tablets are hemostatic agents used to control bleeding associated with surgery and systemic hyperfibrinolysis. The product is commonly utilized in surgical, gynecological, and other clinical settings.
Recognizing the growing demand for neurological therapies, Zhejiang Brothers Pharmaceutical has expanded its pipeline to include treatments for epilepsy, Parkinson's disease, and other neurological disorders.
Lacosamide Injection is a third-generation antiepileptic therapy indicated for adjunctive treatment of partial-onset seizures in patients aged four years and older. The product is covered by China's national medical insurance program and has been selected for the country's tenth round of centralized procurement.
Safinamide Mesylate is an innovative therapy for Parkinson's disease. The product has completed bioequivalence studies and represents an important addition to the company's pipeline targeting neurodegenerative diseases affecting aging populations.
The company is also expanding into treatments for hyperuricemia and gout, strengthening its presence in metabolic disease therapeutics.
Topiroxostat is a novel xanthine oxidase inhibitor used to lower serum uric acid levels in patients with gout and hyperuricemia. Zhejiang Brothers Pharmaceutical has completed bioequivalence studies and is progressing toward regulatory approval. Once commercialized, the formulation will utilize Topiroxostat APIs manufactured within the Brother Group, further enhancing vertical integration.
Building upon the group's long-established expertise in Vitamin B1 and Vitamin B3 manufacturing, Zhejiang Brothers Pharmaceutical has introduced nutritional formulations for both prescription and over-the-counter markets.
Vitamin B1 Tablets are indicated for the prevention and treatment of Vitamin B1 deficiency, peripheral neuritis, digestive disorders, and fatigue associated with insufficient vitamin intake. Because the active ingredient is manufactured internally by the group, the company maintains stable product quality and secure raw material supply.
In addition to its marketed products, Zhejiang Brothers Pharmaceutical maintains a pipeline of more than twenty pharmaceutical products currently under development.
The pipeline includes tablets, capsules, oral liquids, and small-volume injections covering respiratory diseases, gastrointestinal disorders, dermatology, and additional therapeutic areas.
The company follows China's Marketing Authorization Holder (MAH) system, outsourcing commercial manufacturing to qualified pharmaceutical manufacturers while concentrating its own resources on formulation research, process development, regulatory registration, and product commercialization. This asset-light strategy enables faster product launches while maximizing research efficiency.
Key APIs including Iohexol, Iopamidol, Vitamin B1, and Topiroxostat are supplied directly by the group's manufacturing facilities in Jiangsu and Jiangxi. Internal sourcing reduces procurement costs, improves supply stability, and strengthens pricing competitiveness compared with formulation companies that rely entirely on external API suppliers.
The group's established global distribution channels for vitamins, food ingredients, and pharmaceutical raw materials provide a strong foundation for future formulation exports. Within China, the company also benefits from long-term partnerships with pharmaceutical distributors, retail pharmacy chains, and leading hospitals.
Zhejiang Brothers Pharmaceutical has access to the group's centralized research institute, pilot-scale manufacturing platforms, and API process technologies. By integrating API development with formulation research, the company shortens development timelines and improves formulation optimization.
Unlike the group's manufacturing subsidiaries that specialize in bulk vitamins, specialty chemicals, and APIs, Zhejiang Brothers Pharmaceutical focuses exclusively on finished pharmaceutical products.
The company represents a critical step in Brother Enterprises Holding's transformation from a manufacturer of pharmaceutical ingredients into a fully integrated pharmaceutical enterprise combining APIs and finished dosage forms.
Its growing portfolio addresses essential healthcare needs in diagnostic imaging, chronic disease management, neurology, metabolic disorders, and nutritional supplementation, while a robust development pipeline supports long-term growth.
From diagnostic imaging injections to oral therapies for chronic diseases, and from established commercial products to an expanding portfolio of innovative generic medicines, Zhejiang Brothers Pharmaceutical continues to strengthen its position in China's pharmaceutical formulation industry.
Supported by Brother's fully integrated industrial chain, the company combines internal API manufacturing, shared research capabilities, and an extensive commercial network to create sustainable competitive advantages. As generic drug consistency evaluation and centralized procurement continue to reshape China's pharmaceutical market, this vertically integrated business model positions Zhejiang Brothers Pharmaceutical for continued domestic and international growth.
Mobile: +8615371019725
E-mail: sales7@bouling-chem.com
Website: www.brother-pharmaceutical.com
Copyright © Jiangxi Brother Pharmaceutical Co., Ltd. 2026. All right reserved.
